The 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2-4 COPD: results from two 6-week crossover studies

Gregory J Feldman, Jonathan A Bernstein, Alan Hamilton, Michael C Nivens, Lawrence Korducki, Craig LaForce, Gregory J Feldman, Jonathan A Bernstein, Alan Hamilton, Michael C Nivens, Lawrence Korducki, Craig LaForce

Abstract

Abstract: These studies evaluated the 24-h forced expiratory volume in 1 sec (FEV1) profile of once-daily (QD) olodaterol compared to placebo and twice-daily (BID) formoterol in patients with moderate to very severe chronic obstructive pulmonary disease. In two replicate, randomized, double-blind, double-dummy, four-way crossover studies, patients received olodaterol 5 and 10 μg QD, formoterol 12 μg BID, or placebo for 6 weeks in addition to usual-care background maintenance therapy. Co-primary end points were FEV1 area under the curve from 0-12 h (AUC0-12) response (change from baseline) and FEV1 AUC from 12-24 h (AUC12-24) response after 6 weeks, with FEV1 AUC from 0-24 h response identified as a key secondary end point. Other secondary end points included FEV1 AUC from 0-3 h and trough FEV1 responses, as well as corresponding forced vital capacity responses. With both olodaterol doses, FEV1 increased to near-maximal 30 min post-morning dose, which was sustained over 24 h. FEV1 also increased within 30 min post-morning dose of formoterol and was sustained over 12 h; the second formoterol dose resulted in a further increase, sustained for an additional 12 h. FEV1 AUC0-12 and AUC12-24 responses with both QD olodaterol doses and BID formoterol were significantly greater than placebo at 6 weeks (P < .0001). Secondary end-point outcomes were consistent with those of the co-primary end points. These data, together with those from the wider phase III clinical program, provide evidence for the 24-h bronchodilator efficacy of olodaterol QD in this patient population.

Trial registry: ClinicalTrials.gov; NCT00931385 and NCT00932646.

Figures

Figure 1
Figure 1
Study design. BID = twice daily; QD = once daily.
Figure 2
Figure 2
CONSORT diagram illustrating participant flow in (a) study 1222.24 and (b) study 1222.25. AE = adverse event. aAll patients who completed 4 treatment periods.
Figure 3
Figure 3
FEV124-h profiles of olodaterol 5 and 10 μg and formoterol 12 μg BID compared to placebo at week 6 in (a) study 1222.24 and (b) study 1222.25. BID = twice daily; FEV1 = forced expiratory volume in 1 sec.

References

    1. Beier J, Kirsten A-M, Mróz R, Segarra R, Chuecos F, Caracta C, Garcia Gil E. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study. COPD. 2013;10:511–522. doi: 10.3109/15412555.2013.814626.
    1. Bouyssou T, Casarosa P, Naline E, Pestel S, Konetzki I, Devillier P, Schnapp A. Pharmacological characterization of olodaterol, a novel inhaled β2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. J Pharmacol Exp Ther. 2010;334:53–62. doi: 10.1124/jpet.110.167007.
    1. Bouyssou T, Hoenke C, Rudolf K, Lustenberger P, Pestel S, Sieger P, Lotz R, Heine C, Büttner FH, Schnapp A, Konetzki I. Discovery of olodaterol, a novel inhaled β2-adrenoceptor agonist with a 24 h bronchodilatory efficacy. Bioorg Med Chem Lett. 2010;20:1410–1414. doi: 10.1016/j.bmcl.2009.12.087.
    1. Guideline on clinical investigation of medicinal products in the treatment of chronic obstructive pulmonary disease (COPD) 2012.
    1. Ferguson G, Feldman G, Hofbauer P, Hamilton A, Allen L, Korducki L, Sachs P. Lung function efficacy of olodaterol QD delivered via Respimat in COPD patients: Results from two 48-week studies [abstract] Eur Respir J. 2013;42(Suppl 57):5s.
    1. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2013.
    1. Joos G, Aumann JL, Coeck C, Korducki L, Hamilton AL, van Noord J. Comparison of 24-hour FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting B2-agonist, in patients with COPD [abstract] Am J Respir Crit Care Med. 2012;185:abstract A2930.
    1. Koch A, Pizzichini E, Hamilton A, Hart L, Korducki L, De Salvo MC, Paggiaro P. Lung function efficacy of olodaterol QD delivered via Respimat versus placebo and formoterol BID in patients with COPD: two 48-week studies. Barcelona, Spain: Poster P764 presented at the European Respiratory Society Annual Congress; 2013.
    1. Lange P, Aumann J-L, Derom E, Hamilton A, Tetzlaff K, Ting N, van Noord JA. The 24-h FEV1 time profile of olodaterol QD delivered via Respimat® in COPD: Results from two 6-week studies [abstract] Eur Respir J. 2013;42(Suppl 57):982s.
    1. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CPM, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J. Standardisation of spirometry. Eur Respir J. 2005;26:319–338. doi: 10.1183/09031936.05.00034805.
    1. O’Byrne PM, van der Linde J, Cockcroft DW, Gauvreau GM, Brannan JD, FitzGerald M, Watson RM, Milot J, Davis B, O’Connor M, Hart L, Korducki L, Hamilton AL, Boulet L-P. Prolonged bronchoprotection against inhaled methacholine by inhaled BI 1744, a long-acting β2-agonist, in patients with mild asthma. J Allergy Clin Immunol. 2009;124:1217–1221. doi: 10.1016/j.jaci.2009.08.047.
    1. O’Byrne PM, D’Urzo T, Gahlemann M, Hart L, Wang F, Beck E. Dose-finding study of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma [abstract] Am J Respir Crit Care Med. 2012;185:abstract A3963.
    1. Rodrigo GJ, Neffen H. Comparison of indacaterol with tiotropium or twice-daily long-acting β-agonists for stable COPD: a systematic review. Chest. 2012;142:1104–1110. doi: 10.1378/chest.11-2252.
    1. Toy EL, Beaulieu NU, McHale JM, Welland TR, Plauschinat CA, Swensen A, Duh MS. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med. 2011;105:435–441. doi: 10.1016/j.rmed.2010.09.006.
    1. Guidance for Industry: Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products. 1998.
    1. van Noord JA, Korducki L, Hamilton A, Koker P. Four weeks once daily treatment with BI 1744 CL, a novel long-acting β2-agonist, is effective in COPD patients [abstract] Am J Respir Crit Care Med. 2009;179:abstract A6183.
    1. van Noord JA, Smeets JJ, Drenth BM, Rascher J, Pivovarova A, Hamilton AL, Cornelissen PJG. 24-hour bronchodilation following a single dose of the novel β2-agonist olodaterol in COPD. Pulm Pharmacol Ther. 2011;24:666–672. doi: 10.1016/j.pupt.2011.07.006.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅